Dishman Carbogen Amcis growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+8.1%+6.7%
EBITDA+20.6%+19.4%
Net Income+2,914.7%—
EPS (adj.)+2,914.7%—
Total Assets+19.3%+8.0%
Total Equity+14.5%+4.7%
Free Cash Flow+42.3%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹148.86

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,334 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+8.1+6.7
EBITDA+20.6+19.4
Net Income+2914.7—
EPS (adj.)+2914.7—
Total Assets+19.3+8.0
Total Equity+14.5+4.7
Free Cash Flow+42.3—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.